{"id":"doi:10.3390/biomedicines9091271","kind":"review","title":"Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases","authors":["Korneva VA","Kuznetsova TY","Julius U"],"author_count":3,"year":2021,"published":"2021-09-20","venue":"Biomedicines","cited_by":25,"doi":"10.3390/biomedicines9091271","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/biomedicines9091271","archive_url":"https://space-kitty.com/papers/doi:10.3390/biomedicines9091271","updated":null,"pmid":"34572458","pmcid":"PMC8469722","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC8469722/pdf","abstract":"Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Traditional lipid-lowering therapy does not provide a sufficient Lp(a) reduction. For PCSK9 inhibitors a small reduction of Lp(a) levels could be shown, which was associated with a reduction in cardiovascular events, independently of the effect on LDL cholesterol. Another option is inclisiran, for which no outcome data are available yet. Lipoprotein apheresis acutely and in the long run decreases Lp(a) levels and effectively improves cardiovascular prognosis in high-risk patients who cannot be satisfactorily treated with drugs. New drugs inhibiting the synthesis of apolipoprotein(a) (an antisense oligonucleotide (Pelacarsen) and two siRNA drugs) are studied. Unlike LDL-cholesterol, for Lp(a) no target value has been defined up to now. This overview presents data of modern capabilities of cardiovascular risk reduction by lowering Lp(a) level.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases\" by Korneva VA, Kuznetsova TY, Julius U, https://doi.org/10.3390/biomedicines9091271, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}